Post a Comment Print Share on Facebook
Featured Feijóo Policía Inmigración Irán Afganistán

STATEMENT: ImmunAbs announces the conclusion of a phase 1 clinical trial with positive results

(Information sent by the signatory company).

- 2 reads.

STATEMENT: ImmunAbs announces the conclusion of a phase 1 clinical trial with positive results

(Information sent by the signatory company)

SEOUL, South Korea, March 11, 2024/PRNewswire/ -- ImmunAbs, a leading clinical-stage biotechnology company focused on the development of novel antibody therapies, today announced the successful completion of the Phase 1 clinical trial of IM- 101. IM-101 is a humanized monoclonal antibody directed against complement C5, which plays a critical role in complement activation. The complement system is widely recognized for its decisive role in autoimmune diseases.

The randomized, double-blind, placebo-controlled trial was conducted to evaluate the safety, tolerability, and preliminary efficacy of IM-101, a drug targeting the complement system, particularly complement C5. Healthy volunteers were enrolled to receive a single ascending dose of IM-101 or placebo. In particular, IM-101 demonstrated good tolerability, with no serious adverse events or dose-limiting toxicity (DLT) observed at any of the doses tested. ImmunAbs is pleased to report that the trial has successfully met all predefined endpoints.

Dr. Dongjo Kim, CEO of ImmunAbs, expressed his enthusiasm for the results: "We are pleased to report that the top-line results are positive. In this trial, we evaluated a critical biomarker for complement inhibition - the concentration of free C5 in serum-, confirming the efficacy of IM-101 in binding to C5 in humans. These results lay a solid foundation for addressing the unmet medical needs of patients who experience residual symptoms despite receiving current standard treatment. We look forward to see the therapeutic potential of IM-101 in the upcoming phase 2 study."

About ImmunAbs:

ImmunAbs is a clinical-stage biotechnology company founded in 2017. Committed to delivering transformative treatments worldwide, the company aims to develop novel antibody therapies, particularly focusing its efforts on the core program targeting serious autoimmune diseases. ImmunAbs, supported by equity capital and public grants, is actively seeking additional investment and collaboration with the healthcare community to advance IM-101 toward commercialization.

CONTACT: Sabrina Pan,

Photo -

View original content: